Terbium 161

Phase 2Small molecule

TTata Memorial Hospital

Terbium 161 is one of 4 small molecule programs targeting Metastatic Neuroendocrine Tumor. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Metastatic Neuroendocrine TumorRecruiting

Metastatic Neuroendocrine TumorPhase 2

Recruiting

Competition

Competitive Landscape

3 competitors in Metastatic Neuroendocrine Tumor

#DrugCompanyPhaseTrials

Lutathera

AAdvanced Accelerator Applications

Phase 2

1 2

Triapine

VVion Pharmaceuticals

Phase 2

1 3

Terbium 161

TTata Memorial Hospital

Phase 2

1 4

Gallium Ga 68-DOTATATE

MMayo Clinic

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2029

Phase 2Recruiting

Metastatic Neuroendocrine Tumor

NCT07404176

Clinical

Trials by Indication[1]

Metastatic Neuroendocrine Tumor1 trial

Study to Assess the Safety and Effectiveness of Novel Radiopharmaceutical Terbium-161 DOTATATE in Metastatic Neuroendocrine Tumors

Recruiting·TTata Memorial Hospital·Phase 2·NCT07404176·20 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Terbium 161. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Terbium 161 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Terbium 161. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Tata Memorial Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: TTata Memorial Hospital

Terbium 161

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2029

Trials by Indication[1]

Metastatic Neuroendocrine Tumor1 trial

References

Drug Info

Quick Facts

Related News